Sector pending / Medicinal Chemicals and Botanical ProductsUpdated 2026-05-10 22:07 UTC

FRA/OCD1 stock hub

FRA/OCD1 has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

FRA/OCD1is not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

282.8M

Frankfurt Stock Exchange

Market data

Price

Recent price action with selectable time range.

FRA/OCD1FRA/OCD1

—

Loading chart…

In the news

Latest news · FRA/OCD1

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E22.3

P25 n/aP50 n/aP75 n/a

Trailing P/E17.5

P25 n/aP50 n/aP75 n/a

ROE27.1

P25 n/aP50 n/aP75 n/a

ROIC63.5

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All FRA/OCD1 market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

191

Groups with data

Currency

USD

Showing 191 of 191 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	DE
Employees	117
Employees Change	-2%
Employees Change Percent	-1.89
Enterprise value	EUR 228.4M
Exchange	Frankfurt Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medicinal Chemicals and Botanical Products
Last refreshed	2026-05-10
Market cap	EUR 282.8M
Price	EUR 3.58
Price currency	EUR
Rev Per Employee	966,750.4x
Sic	2833
Symbol	fra/OCD1
Website	https://www.niagenbioscience.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.72%
EV Earnings	14.13x
EV/EBIT	24.22x
EV/EBITDA	20.2x
EV/FCF	64.14x
EV/Sales	2.06x
FCF yield	1.26%
Forward P/E	22.34x
P/B ratio	3.96x
P/E ratio	17.49x
P/S ratio	2.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	8.51%
EBITDA Margin	9.19%
FCF margin	3.15%
Gross margin	64.28%
Gross Profit	EUR 72.7M
Gross Profit Growth	24.27%
Gross Profit Growth Q	3.34%
Gross Profit Growth3 Y	22.34%
Gross Profit Growth5 Y	18.29%
Net Income	EUR 16.2M
Net Income Growth	32.13%
Net Income Growth Q	24.79%
Pretax Margin	15.1%
Profit Margin	14.29%
Profit Per Employee	EUR 138,153
ROA	7.09
Roa5y	-8.87
ROCE	12.13
ROE	27.07
Roe5y	-26.69
ROIC	63.52
Roic5y	-94.24

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-53.23%
Cagr3y	43.16%
Cagr5y	-12.55%
EPS Growth	17.35
EPS Growth Q	16.67
FCF Growth	-78.99%
OCF Growth	-77.52%
Revenue Growth	20.84x
Revenue Growth Q	3.26x
Revenue Growth3 Y	19.02x
Revenue Growth5 Y	16.96x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 1.33
Assets	EUR 99.2M
Cash	EUR 57.7M
Current Assets	EUR 89.1M
Current Liabilities	EUR 19.4M
Debt	EUR 2.2M
Debt EBITDA	EUR 0.19
Debt Equity	EUR 0.03
Debt FCF	EUR 0.63
Equity	EUR 71.4M
Interest Coverage	132.1
Liabilities	EUR 27.8M
Long Term Assets	EUR 10M
Long Term Liabilities	EUR 8.4M
Net Cash	EUR 55.5M
Net Cash By Market Cap	EUR 19.62
Net Cash Growth	23.17%
Net Debt EBITDA	EUR -5.34
Net Debt Equity	EUR -0.78
Net Debt FCF	EUR -15.58
Tangible Book Value	EUR 66.6M
Tangible Book Value Per Share	EUR 0.84

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.61
Inventory Turnover	2.65
Net Working Capital	EUR 14.6M
Quick ratio	3.49
Working Capital	EUR 71.4M
Working Capital Turnover	EUR 1.64

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-7.04%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-53.2%
200-day SMA	5.68
3Y total return	193.44%
50-day SMA	3.88
50-day SMA vs 200-day SMA	50under200
5Y total return	-48.86%
All Time High	19
All Time High Change	-81.16%
All Time High Date	2021-02-26
All Time Low	1.17
All Time Low Change	205.98%
All Time Low Date	2023-04-26
ATR	0.19
Ch YTD	-33.08
High	3.58
High52	12.4
High52 Date	2025-06-16
High52ch	-71.13%
Low	3.32
Low52	3.32
Low52 Date	2026-05-08
Low52ch	7.83%
Ma50ch	-7.73%
Price vs 200-day SMA	-36.94%
RSI	43.4
RSI Monthly	43.61
RSI Weekly	29.38
Sharpe ratio	-0.98x
Sortino ratio	-1.27
Total Return	-7.04%
Tr YTD	-33.08
Tr1m	-1.1%
Tr1w	-7.73%
Tr3m	-12.25%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR 9.6M
Operating Income Growth	-16.09
Operating Income Growth Q	-66.97
Operating margin	8.51

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	52,246,688%
Net Borrowing	-7,631.7
Shares Insiders	29.59%
Shares Institutions	46.04%
Shares Qo Q	0.14%
Shares Yo Y	7.04%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -2.3M
Average Volume	34.25x
Bv Per Share	0.9
CAPEX	EUR -278,403
Ch1m	-1.1
Ch1w	-7.73
Ch1y	-53.2
Ch3m	-12.25
Ch3y	193.4
Ch5y	-48.86
Ch6m	-34.31
Change	-1.65%
Change From Open	7.83
Close	3.64
Days Gap	-8.79
Depreciation Amortization	747,054.5
Dollar Volume	64.44
Earnings Date	2026-05-06
EBIT	EUR 9.6M
EBITDA	EUR 10.4M
EPS	EUR 0.18
F Score	5
FCF	EUR 3.6M
FCF EV Yield	1.56x
Financing CF	1,319,163
Fiscal Year End	December
Founded	1,999
Graham Number	2.04031
Graham Upside	-43.01
Income Tax	EUR 918,471
Investing CF	4,323,491
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Ma150	4.87
Ma150ch	-26.53%
Ma20	3.85
Ma20ch	-6.96%
Net CF	9,482,191
Next Earnings Date	2026-08-05
Open	3.32
P FCF Ratio	79.4
P OCF Ratio	73.64
Position In Range	100
Ppne	2,812,690
Price Date	2026-05-08
Price EBITDA	EUR 27.21
Ptbv Ratio	4.24
Relative Volume	8.01x
Revenue	113,109,797x
SBC By Revenue	5.14x
Share Based Comp	5,817,848
Tax By Revenue	0.81x
Tax Rate	5.38%
Tr6m	-34.31%
Volume	0

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does FRA/OCD1 pay a dividend?

Capital-return profile for this ticker.

Performance

FRA/OCD1 stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns FRA/OCD1?

Insider, institutional, and short-interest positioning.

Institutional ownership

+46.0%

Share of float held by funds and institutions

Insider ownership

+29.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+7.0%

Negative means the company is buying back shares.

Technical

FRA/OCD1 momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.4

Neutral momentum band

Price vs 200-day MA

-36.9%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

-0.98

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About FRA/OCD1

Hub-level FAQ points readers to the deeper analysis pages.

What is the current fra/OCD1 stock rating?

fra/OCD1 is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full fra/OCD1 analysis?

The full report lives at /stocks/fra/OCD1/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for fra/OCD1?

The latest report frames fra/OCD1 around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the fra/OCD1 page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.